THE CLINICAL DEVELOPMENT OF LUMATEPERONE (ITI-007) FOR THE TREATMENT OF SCHIZOPHRENIA

被引：0
|
作者：
Vanover, Kimberly [1 ]
Correll, Christoph [2 ]
Dmitrienko, Alex [3 ]
Glass, Steve [1 ]
O'Gorman, Cedric [1 ]
Saillard, Jelena [1 ]
Weingart, Michal [1 ]
Mates, Sharon [1 ]
Davis, Robert [1 ]
机构：
[1] Intra Cellular Therapies Inc, New York, NY USA
[2] Zucker Hillside Hosp, New York, NY USA
[3] Mediana Inc, Redmond, WA USA
来源：
SCHIZOPHRENIA BULLETIN | 2017年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
24
引用
收藏
页码：S16 / S16
页数：1
相关论文
共 50 条
  • [1] Clinical Development of ITI-007 for the Treatment of Schizophrenia
    Vanover, Kimberly
    Davis, Robert
    O'Gorman, Cedric
    Saillard, Jelena
    Weingart, Michal
    Mates, Sharon
    [J]. NEUROPSYCHOPHARMACOLOGY, 2015, 40 : S548 - S549
  • [2] The Novel Antipsychotic Lumateperone (Iti-007) in the Treatment of Schizophrenia: A Systematic Review
    Longo, Giulio
    Cicolini, Angelica
    Orsolini, Laura
    Volpe, Umberto
    [J]. BRAIN SCIENCES, 2023, 13 (12)
  • [3] Long-Term Safety for Lumateperone (ITI-007) in the Treatment of Schizophrenia
    Vanover, Kimberly
    Correll, Christoph
    Weingart, Michal
    Saillard, Jelena
    Hossain, Shawn
    Glass, Steven
    Kozauer, Susan
    Satlin, Andrew
    Davis, Robert
    [J]. NEUROPSYCHOPHARMACOLOGY, 2018, 43 : S328 - S329
  • [4] Efficacy of Lumateperone (ITI-007) in Depression Symptoms Associated With Schizophrenia
    Satlin, Andrew
    Davis, Robert
    Durgam, Suresh
    Vanover, Kimberly
    Kozauer, Susan
    Huo, Jason
    Mates, Sharon
    McIntyre, Roger
    [J]. NEUROPSYCHOPHARMACOLOGY, 2020, 45 (SUPPL 1) : 248 - 249
  • [5] The clinical development of lumateperone (ITI-007) for the treatment of bipolar depression: scientific rationale and clinical design
    Davis, R.
    O'gorman, C.
    Mates, S.
    Vanover, K.
    [J]. BIPOLAR DISORDERS, 2017, 19 : 61 - 61
  • [6] Lumateperone (ITI-007) in the Treatment of Bipolar Depression: Results From a Randomized Clinical Trial
    Durgam, Suresh
    Satlin, Andrew
    Vanover, Kimberly
    Davis, Robert
    Kozauer, Susan
    Chen, Richard
    Mates, Sharon
    Calabrese, Joseph
    [J]. NEUROPSYCHOPHARMACOLOGY, 2019, 44 (SUPPL 1) : 450 - 451
  • [7] Advancing the Clinical Development of ITI-007 for the Treatment of Schizophrenia - Safety and Tolerability Data
    Davis, Robert
    Glass, Steven
    Saillard, Jelena
    Weingart, Michal
    O'Gorman, Cedric
    Correll, Christoph
    Mates, Sharon
    Vanover, Kimberly
    [J]. NEUROPSYCHOPHARMACOLOGY, 2016, 41 : S227 - S227
  • [8] ITI-007, A NEW APPROACH TO THE TREATMENT OF SCHIZOPHRENIA
    Vanover, Kimberly E.
    Davis, Robert E.
    Mates, Sharon
    [J]. SCHIZOPHRENIA RESEARCH, 2014, 153 : S21 - S21
  • [9] Lumateperone (iti-007) in the treatment of bipolar depression: efficacy across symptoms
    Durgam, Suresh
    Davis, Robert E.
    Kozauer, Susan G.
    Saleem, Ameen
    Huo, Jason
    Calabrese, Joseph R.
    [J]. BIPOLAR DISORDERS, 2022, 24 : 36 - 36
  • [10] Lumateperone (ITI-007) in the treatment of bipolar depression: Efficacy across symptoms
    Durgam, Suresh
    Satlin, Andrew
    Vanover, Kimberly E.
    Davis, Robert E.
    Kozauer, Susan G.
    Huo, Jason
    Mates, Sharon
    Calabrese, Joseph
    [J]. BIPOLAR DISORDERS, 2020, 22 : 112 - 112
12345